The White House recently issued an executive order accelerating the use of psychedelics, such as psilocybin, MDMA, and ibogaine, in research and clinical trials. This order, however, does not change the current legal status of any of them. In this Q&A, Life Science Connect’s Morgan Kohler caught up with Joseph Tucker, Ph.D., CEO of Enveric Biosciences, to discuss the implications of this order and what it means for the industry.
